胰高血糖素样肽-1受体激动剂在妊娠期的使用:综述
胰高血糖素样肽-1受体激动剂(GLP-1 RA)用于治疗2型糖尿病和肥胖,因减重效果使部分既往月经稀发不孕女性在用药期间意外妊娠。动物研究显示不良结局,人类无前瞻性研究,病例报告、队列研究和人群研究未显示先天畸形模式。近期一项大型观察性人群队列研究比较围受孕期暴露于GLP-1 RA与胰岛素,作者结论为重大先天畸形风险未显著增加,但缺乏母体血糖控制和糖尿病胎儿病变信息。目前证据不足以预测围受孕期暴露的任何不良效应,建议用药期间所有患者避孕。
要点
- GLP-1 RA减重可致既往不孕女性用药期间意外妊娠,围受孕期暴露咨询证据不足。
- 小动物孕期暴露研究显示胎仔生长下降、骨骼和内脏异常及胚胎死亡。
- 人类无前瞻性研究,病例报告、队列和人群研究未显示先天畸形模式。
核心结论
- 目前证据不足以预测围受孕期暴露于GLP-1 RA的任何不良效应或其缺失。
- 作者建议所有患者在使用GLP-1 RA期间避孕以防止意外妊娠。
研究设计与样本
- 综述,检索范围未在摘要中报告。
主要发现
- 小动物孕期暴露于GLP-1 RA的研究显示子代不良结局,包括胎儿生长下降、骨骼和内脏异常及胚胎死亡。
- 人类无前瞻性研究,病例报告、队列研究和人群研究未显示婴儿先天畸形模式。
- 近期一项大型观察性人群队列研究检查938例患2型糖尿病的妊娠,比较围受孕期暴露于GLP-1 RA与胰岛素,作者结论为服用GLP-1 RA患者重大先天畸形风险未显著增加。
- 该队列研究无母体血糖控制或糖尿病胎儿病变信息,而糖尿病胚胎病变直接与母体高血糖程度相关而非糖尿病诊断本身。
- 关于胎儿生长受限、胚胎或胎儿死亡或其他潜在并发症的证据很少。
临床怎么用
- 作者建议所有患者在使用GLP-1 RA期间使用避孕措施以防止意外妊娠。
- 目前应告知患者证据不足以预测围受孕期暴露于GLP-1 RA的任何不良效应或其缺失。
局限性
- 人类无前瞻性研究。
- 近期大型观察性人群队列研究无母体血糖控制或糖尿病胎儿病变信息。
- 关于胎儿生长受限、胚胎或胎儿死亡或其他潜在并发症的证据很少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glucagon-like peptide-1 receptor agonists are peptide analogues that are used to treat type 2 diabetes mellitus and obesity. The first medication in this class, exenatide, was approved in 2005, and these medications, specifically semaglutide, have become more popular in recent years due to their pronounced effects on glycemic control, weight reduction, and cardiovascular health. Due to successful weight loss from these medications, many women previously diagnosed with oligomenorrhea and unable to conceive have experienced unplanned pregnancies while taking the medications. However, there are currently little data for clinicians to use in counseling patients in cases of accidental periconceptional exposure. In some studies examining small animals exposed to glucagon-like peptide-1 receptor agonists in pregnancy, there has been evidence of adverse outcomes in the offspring, including decreased fetal growth, skeletal and visceral anomalies, and embryonic death. Although there are no prospective studies in humans, case reports, cohort studies, and population-based studies have not shown a pattern of congenital anomalies in infants. A recent large, observational, population-based cohort study examined 938 pregnancies affected by type 2 diabetes mellitus and compared outcomes from periconceptional exposure to glucagon-like peptide-1 receptor agonists and insulin. The authors concluded there was not a significantly increased risk of major congenital malformations in patients taking glucagon-like peptide-1 receptor agonists, although there was no information on maternal glycemic control or diabetic fetopathy. As diabetic embryopathy is directly related to the degree of maternal hyperglycemia and not the diagnosis of diabetes itself, it is not possible to make this conclusion without this information. Furthermore, there is little evidence available regarding fetal growth restriction, embryonic or fetal death, or other potential complications. At this time, patients should be counseled there is not enough evidence to predict any adverse effects, or the lack thereof, of periconceptional exposure of glucagon-like peptide-1 receptor agonists during pregnancy. We recommend that all patients use contraception to prevent unintended pregnancy while taking glucagon-like peptide-1 receptor agonists.
引用
- Drummond RF, Seif KE, Reece EA, et al. Glucagon-like peptide-1 receptor agonist use in pregnancy: a review. Am J Obstet Gynecol. 2024. PMID: 39181497. doi:10.1016/j.ajog.2024.08.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。